Viloxazine is a type of medicine used to treat depression. It works similarly to another medicine called Imipramine. It's often taken as a pill. Doctors prescribe it to help people feel better when they are feeling down or sad.
Every report comes from a Lived member, sent anonymously.
Have you tried Qelbree (Viloxazine) for ADHD?
Viloxazine, sold in the US under the brand name Qelbree, is a prescription medicine for attention-deficit/hyperactivity disorder (ADHD) in adults and in children 6 years and older. It is a non-stimulant, so it is not related to methylphenidate or amphetamine, the stimulant medicines most often used for ADHD. That makes it one option for people who did not get enough benefit from a stimulant, could not tolerate one, or prefer not to take one. Its closest relative among ADHD treatments is atomoxetine (Strattera), another non-stimulant that works in a similar way. The molecule itself is not new. An immediate-release form was sold in the UK and other European countries as an antidepressant from the 1970s until it was withdrawn for commercial reasons, and it was never approved in the US for depression. Qelbree is a once-daily extended-release version developed for ADHD, approved by the FDA for children and teenagers in 2021 and for adults in 2022.
Norepinephrine is a chemical messenger the brain uses to help regulate attention and behavior. After it carries a signal from one nerve cell to the next, a transporter normally pulls it back into the cell that released it. Viloxazine blocks that transporter, which leaves more norepinephrine available to keep acting. It also acts on some serotonin receptors, which may add to its effect. The official prescribing information says the exact reason it improves ADHD is not fully understood. In practice, the benefit builds over weeks of daily use rather than appearing with each dose, which is one way it differs from stimulants.
Qelbree comes as extended-release capsules taken once a day, with or without food. The prescriber starts with a low dose and may raise it about once a week, depending on how well it works and how well it is tolerated. Starting and maximum doses differ for children 6 to 11, teenagers and adults, and the highest doses are approved only for adults. Swallow the capsule whole, without cutting, crushing or chewing it. For someone who cannot swallow capsules, the capsule can be opened and all of its contents sprinkled on a spoonful of applesauce or pudding, then swallowed without chewing: within 15 minutes when mixed with pudding, or within 2 hours with applesauce. The mixture should not be saved for later. The kidneys clear viloxazine from the body, so people with severe kidney disease start on a lower dose and have a lower maximum. It is worth asking the prescriber in advance what to do about a missed dose.
Sleepiness and tiredness are among the most common effects, which can surprise people who expect an ADHD medicine to feel energizing. In children and teenagers, other common effects are reduced appetite, nausea, vomiting, trouble sleeping and irritability. Adults most often report trouble sleeping, headache, sleepiness, tiredness, nausea, reduced appetite, dry mouth and constipation. Until you know how it affects you, avoid driving or other tasks that need full alertness. Viloxazine can raise heart rate and diastolic blood pressure (the bottom number, the pressure in the arteries between heartbeats). In the adult trial, about 3 in 10 people taking it had a rise in heart rate of 20 beats per minute or more at some point, compared with about 1 in 8 on placebo. This is why heart rate and blood pressure are checked before starting, after dose increases and from time to time during treatment. In short trials, children taking it gained slightly less weight than children on placebo, and teenagers lost a small amount on average, so weight is tracked during treatment.
Qelbree carries a boxed warning, the FDA's most prominent type, about suicidal thoughts and behaviors. In clinical trials these were uncommon, but they were reported more often in children and adults taking Qelbree than in those taking placebo. The risk is greatest in the first few months and after any dose change, up or down. The person taking it and their family should watch for new or sudden changes such as worsening depression, anxiety, irritability, agitation or restlessness, panic attacks, aggression or acting on dangerous impulses, and call the prescriber right away if they appear. Thoughts of suicide or dying also need a call to the prescriber right away; if someone has attempted suicide or is in immediate danger, get emergency help. Medicines that act on norepinephrine can set off mania in people with bipolar disorder. Before starting, the prescriber asks about any personal or family history of bipolar disorder, depression or suicide. Greatly increased energy, racing thoughts, severe trouble sleeping or reckless behavior should be reported promptly. Viloxazine must not be taken with a monoamine oxidase inhibitor (MAOI), an older type of antidepressant, or within 14 days of stopping one, because the combination can cause a dangerous spike in blood pressure. It also strongly slows a liver enzyme called CYP1A2, which some medicines depend on to be cleared, so those medicines can build up to harmful levels. It should not be combined with tizanidine (a muscle relaxant), theophylline (a lung and asthma medicine), duloxetine (Cymbalta, an antidepressant also used for nerve pain), ramelteon or tasimelteon (sleep medicines) or alosetron (a treatment for severe irritable bowel syndrome). It has milder effects on how some other medicines are processed, so give the prescriber and pharmacist a full list, including over-the-counter products and supplements. Animal studies suggest viloxazine may cause harm in pregnancy, and human data are too limited to judge the risk. Anyone who becomes pregnant, or thinks they may be, should tell the prescriber promptly to decide whether to stop. Small amounts pass into breast milk, and effects on a breastfed baby are not known.
Improvement usually builds gradually. In the adult trial, symptoms began improving within 2 to 3 weeks, and doses are often adjusted over the first several weeks. On average, the improvement in trials was clear compared with placebo but modest, and it is generally thought to be smaller than what stimulants achieve, although no large trial has compared them directly. Some people respond well and others not enough, so it is common to agree on a trial period and a point at which to review it. Early follow-up usually covers heart rate, blood pressure, mood, sleep and, for children, appetite and weight. ADHD treatment can continue for long periods, and the prescriber should periodically reassess whether the medicine is still needed and the dose is still right. Talk with the prescriber before stopping or changing the dose.
Last reviewed • Oct 2026
Educational content, not medical advice.
It works really well I think haven’t been taking it very long but would like to hear from someone else that has